Victory Capital Management Inc. decreased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 89.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,583 shares of the biotechnology company’s stock after selling 86,592 shares during the quarter. Victory Capital Management Inc.’s holdings in Viking Therapeutics were worth $63,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Advisor Group Holdings Inc. grew its stake in shares of Viking Therapeutics by 7.3% in the 2nd quarter. Advisor Group Holdings Inc. now owns 77,765 shares of the biotechnology company’s stock valued at $466,000 after buying an additional 5,320 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Viking Therapeutics by 22.2% in the 2nd quarter. Alliancebernstein L.P. now owns 79,400 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 14,400 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Viking Therapeutics by 139.6% in the 1st quarter. Squarepoint Ops LLC now owns 106,255 shares of the biotechnology company’s stock valued at $672,000 after buying an additional 61,907 shares in the last quarter. Cornerstone Capital Inc. lifted its holdings in Viking Therapeutics by 4.0% in the 1st quarter. Cornerstone Capital Inc. now owns 133,645 shares of the biotechnology company’s stock worth $845,000 after purchasing an additional 5,180 shares during the last quarter. Finally, Caxton Associates LP lifted its holdings in Viking Therapeutics by 94.7% in the 1st quarter. Caxton Associates LP now owns 38,750 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 18,849 shares during the last quarter. 48.68% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on VKTX. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of Viking Therapeutics in a report on Thursday, June 17th. SVB Leerink assumed coverage on Viking Therapeutics in a report on Sunday, June 20th. They issued a “buy” rating and a $18.00 target price for the company. Raymond James upped their price target on Viking Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Thursday, July 29th. B. Riley reiterated a “buy” rating and set a $15.00 price target on shares of Viking Therapeutics in a report on Friday, June 18th. Finally, Zacks Investment Research upgraded Viking Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.00.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, July 28th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Analysts anticipate that Viking Therapeutics, Inc. will post -0.81 earnings per share for the current year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214.
Further Reading: 52-week highs
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.